Skip to content

Olfactory training with essential oils in patients with olfaction sequelae after COVID-19

Advanced olfactory training in post-COVID patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3f8dm6q
Enrollment
Unknown
Registered
2022-01-23
Start date
2021-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anosmia

Interventions

Classic olfactory training group (COT): 50 patients with post-COVID-19 olfactory dysfunction will undergo olfactory training with 4 essential oils (carnation, rose, eucalyptus and lemon). Modified olf
G16.500.275.640

Sponsors

Complexo Hospital de Clínicas da Universidade Federal do Paraná
Lead Sponsor
Complexo Hospital de Clínicas da Universidade Federal do Paraná
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients who complain of anosmia or hyposmia after SARS-CoV-2 infection less than 3 months after symptom onset; convalescing from her COVID-19 disease, with onset of disease symptoms for at least 4 weeks; Patients who underwent RT-PCR test at symptom onset, with detection of SARS-CoV-2; Patients who can give valid written informed consent; Patients motivated to participate in the study; Adult patients aged 18-60 years.

Exclusion criteria

Exclusion criteria: Patients who cannot give valid written informed consent; Patients with a previous history of more than one SARS-CoV-2 infection Patients with nasosinusal diseases such as chronic rhinosinusitis or nasal masses; History of previous traumatic brain injury with olfactory sequelae; History of olfaction disorder prior to SARS CoV-2 infection; Patients with any diagnosed neurological disease known to affect olfactory function; Patients unable to read Portuguese; Patients who are already using an oral glucocorticoid; Patients who have already started some form of therapy for the olfactory disorder caused by COVID-19; Known hypersensitivity to any item used in any of the proposed olfactory training;

Design outcomes

Primary

MeasureTime frame
The primary outcome assessed will be improvement in olfaction (periods 4, 12, 24 and 52 weeks after starting treatment). The evaluation of smell is based on the comparison of results from before and after the olfactory rehabilitation obtained from a single method of the two methods: olfactory identification results obtained from the University of Pennsylvania Smell Identification Test (UPSIT); Subjective assessment of patients using a visual analogue scale for the following complaints: loss of ability to smell; loss of ability to sense flavors; nasal symptoms in the last 14 days; how much the difficulty in smelling bothers; how much the difficulty in feeling flavors bothers.

Secondary

MeasureTime frame
Adherence to treatment will be evaluated, which will be evaluated in percentage of days in which the olfactory training was correctly performed. It is expected that the adherence of patients undergoing therapy with the advanced olfactory training kit of 24 essences will not be inferior to the classic olfactory training of 4 essences or the modified olfactory training of 12 essences, since the perception of smell improvement and the greater alternation of essences may be able to motivate the patient to maintain therapy., which will be evaluated as a percentage of days in which the olfactory training was correctly performed. It is expected that the adherence of patients undergoing therapy with the advanced olfactory training kit of 24 essences will not be inferior to the classic olfactory training of 4 essences or the modified olfactory training of 12 essences, since the perception of smell improvement and the greater alternation of essences may be able to motivate the patient to maintain therapy.

Countries

Brazil

Contacts

Public ContactÍcaro Pires
icaroatp@gmail.com+5541991846369

Outcome results

None listed

Source: REBEC (via WHO ICTRP)